Platelet ATP release assay

The ADP produced in the platelet release reaction is converted to ATP by the action of phosphoenolpyruvate (PEP), and the total amount of ATP and ADP released from the platelets can be calculated by fluorescence intensity measurement. Decreased platelet ATP release is seen in myelodysplastic syndrome; in patients with primary thrombocytopenic purpura. ADP and adrenal inducers reduced platelet-releasing ATP levels, while collagen-induced release was normal; it was also reduced in multiple myeloma and Hodgkin's disease. In addition, ATP levels are also reduced in certain depot conditions and after taking antiplatelet agents. Basic Information Specialist classification: growth and development examination classification: blood examination Applicable gender: whether men and women apply fasting: fasting Tips: Try to reduce the amount of exercise before blood draw, do not eat food, keep fasting, you can drink a small amount of water, in addition to some drugs that must be taken on time, try to take other drugs to the blood and then take it, so as not to some experiments The result is interference. Normal value (1) When ADP (3.6 × 10 -6 mol/L) was added, the ATP release amount was 1.8 ± 0.8 μmol/1011 platelets. (2) When adrenaline (9 × 10 -6 mol / L) was added, the ATP release amount was 1.7 ± 0.4 μmol/1011 platelets. (3) When collagen (0.28 g/L) was added, the ATP release amount was 1.6 ± 0.3 μmol/1011 platelets. Clinical significance Decreased platelet ATP release is seen in myelodysplastic syndrome in patients with primary thrombocytopenic purpura. ADP and adrenal inducing agents reduce the amount of platelet-releasing ATP, while collagen-induced release is normal, and is also reduced in multiple myeloma and Hodgkin's disease. In addition, ATP levels are also reduced in certain depot conditions and after taking antiplatelet agents. Low results may be diseases: He Jiejin disease, high purple sputum results may be diseases: precautions for head trauma The level of glandular nucleotides decreased during DIC and sepsis. Inspection process (1) Add 1 ml of inactivation buffer and 1 ml of activation buffer to each of the two tubes. (2) Add 50 μl of the specimen, shake well, incubate for 10 min at room temperature, then place the specimen in a water bath at 80-100 ° C for 6 min, then move to an ice bath. (3) 10 μl of the standard or specimen was added to a small test tube containing 100 μl of a fluorescein-luciferase solution, and the absorbance was measured and repeated three times to obtain an average value. Not suitable for the crowd 1. Patients who have taken contraceptives, thyroid hormones, steroid hormones, etc., may affect the results of the examination and prohibit patients who have recently taken the drug history. 2, special diseases: patients with hematopoietic function to reduce disease, such as leukemia, various anemia, myelodysplastic syndrome, etc., unless the examination is essential, try to draw less blood. Adverse reactions and risks 1, subcutaneous hemorrhage: due to pressing time less than 5 minutes or blood draw technology is not enough, etc. can cause subcutaneous bleeding. 2, discomfort: the puncture site may appear pain, swelling, tenderness, subcutaneous ecchymosis visible to the naked eye. 3, dizzy or fainting: in the blood draw, due to emotional overstress, fear, reflex caused by vagus nerve excitement, blood pressure decreased, etc. caused by insufficient blood supply to the brain caused by fainting or dizziness. 4. Risk of infection: If you use an unclean needle, you may be at risk of infection.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.